IMMUNOLOGICAL DISORDERS

Spotting the troublemakers

a method for identifying potentially pathogenic T_H17 cells in humans

T helper 17 ($T_{\rm H}$ 17) cells produce interleukin-17 (IL-17) and are thought to promote various inflammatory conditions, including Crohn's disease. However, not all $T_{\rm H}$ 17 cells are pathogenic, and some have beneficial immunoregulatory functions. As such, there is interest in developing therapeutics that specifically target disease-promoting $T_{\rm H}$ 17 cells. A recent study by Ramesh et al. now describes a method for distinguishing pathogenic from non-pathogenic $T_{\rm H}$ 17 cells in humans.

Recent studies in mice have shown that pathogenic $T_{\rm H}17$ cells produce interferon- γ (IFN γ) and express high levels of the IL-23 receptor (IL-23R). Previous work has also suggested that human memory $T_{\rm H}17$ cells can be divided into two main subsets on the basis of chemokine receptor expression — CCR6+CCR4hi $T_{\rm H}17$ cells express IL-17, but not IFN γ , whereas CCR6+CXCR3hi $T_{\rm L}17$

cells express both IL-17 and IFNy. Consistent with this, Ramesh et al. identified similar T₁₁17 cell populations in blood from healthy adults. Compared with CCR6+CCR4hi T, 17 cells, CCR6+CXCR3hi T₁₁17 cells produced lower levels of IL-17 but expressed higher levels of mRNAs encoding IL-23R and other proinflammatory mediators, such as CC-chemokine ligand 3 (CCL3), CCL4, CCL5 and granzyme B. By contrast, CCR6+CCR4hi T, 17 cells expressed higher levels of mRNAs encoding anti-inflammatory mediators, such as IL-10 and the IL-1R antagonist protein. However, despite these differences in IL-23R expression, both populations showed a similar, weak response to IL-23mediated stimulation in vitro. The authors therefore hypothesized that potentially pathogenic IL-23responsive T_H17 cells represent only a minor subset of the CCR6+CXCR3hi T cell population.

In agreement with this, they were able to identify a subpopulation of CCR6+CXCR3hi T cells that was enriched for pathogenic characteristics, including enhanced responsiveness to IL-23, as determined by increased phosphorylation of signal transducer and activator of transcription 3 (STAT3) and increased production of IL-17. These cells specifically expressed multidrug resistance protein 1 (MDR1; also known as P-glycoprotein), which is a membrane transporter that can promote the efflux of a broad range of substrates. Notably, the authors

found that MDR1⁺ memory T cells were enriched in biopsy samples from the inflamed gut of patients with Crohn's disease compared with either peripheral blood from the patients or biopsy samples from non-inflamed gut. Furthermore, MDR1⁺ T cells from inflamed gut tissue expressed genes associated with pathogenic T_H17 cell activity, whereas MDR1⁻ T cells from the same biopsy samples expressed genes associated with non-pathogenic T_H17 cells.

Finally, in *ex vivo* culture experiments, the authors showed that MDR1⁺ T_H17 cells from healthy humans are resistant to the immunosuppressive effects of glucocorticoids. Strikingly, treatment with glucocorticoids actually led to the enrichment of MDR1⁺ T_H17 cells within mixed T cell cultures. Notably, patients with Crohn's disease often develop steroid-resistant disease, but the reasons for this have not been clear.

Taken together, these findings have important clinical implications as they not only describe a method for identifying potentially pathogenic $T_{\rm H}17$ cells in humans but also suggest a possible mechanism for why certain patients with Crohn's disease do not respond to glucocorticoid therapy.

Yvonne Bordon, Senior Editor, Nature Reviews Immunology This article is modified from the original in Nature Rev. Immunol. (http://dx.doi.org/ 10.1038/pri3610).

ORIGINAL RESEARCH PAPER Ramesh, R. et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 211, 89–104 (2014)

